Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 14/20 | 0.53 |
| ▸ | EIF2S1 | P05198 | 12/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23044033 | 1.00 | EIF2AK3 (0.53) | EIF2AK3EIF2S1FLT3METAXL | |
| SCHEMBL29683975 | 1.00 | EIF2AK3 (0.53) | EIF2AK3EIF2S1FLT3METAXL | |
| SCHEMBL23044036 | 1.00 | EIF2AK3 (0.53) | EIF2AK3EIF2S1FLT3METAXL | |
| SCHEMBL23044625 | 1.00 | EIF2AK3 (0.53) | EIF2AK3EIF2S1FLT3METAXL | |
| SCHEMBL29684516 | 1.00 | EIF2AK3 (0.53) | EIF2AK3EIF2S1FLT3METAXL | |
| SCHEMBL23057893 | 0.92 | EIF2AK3 (0.55) | EIF2AK3EIF2S1FLT3METAXL | |
| SCHEMBL30060899 | 0.92 | EIF2AK3 (0.55) | EIF2AK3EIF2S1FLT3METAXL | |
| SCHEMBL23043896 | 0.91 | EIF2AK3 (0.53) | EIF2AK3EIF2S1FLT3METAXL | |
| SCHEMBL23043897 | 0.91 | EIF2AK3 (0.53) | EIF2AK3EIF2S1FLT3METAXL | |
| SCHEMBL23044035 | 0.91 | EIF2AK3 (0.53) | EIF2AK3EIF2S1FLT3METAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021908-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | Hibercell, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. | 2022-11-10 | — | — | US | disclosed |
| EP-4021908-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | Hibercell, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | EEF2K, ATF4, MAPKAPK2 | EIF2AK3 96/4885EIF2S1 380/4885FLT3 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.